Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain-Reference-Cited by-同舟云学术

Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain

Published:2013-06-21 Issue:3 Volume:16 Page:273-279
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Balañá C.,Vaz M. A.,Lopez D.,de la Peñas R.,García-Bueno J. M.,Molina-Garrido M. J.,Sepúlveda J. M.,Cano J. M.,Bugés C.,Sanz S. M.,Arranz J. L.,Perez-Segura P.,Rodriguez A.,Martin J. M.,Benavides M.,Gil M.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12094-013-1068-3.pdf

Reference23 articles.

1. Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, et al. Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer. 2012;48:1532–42.

2. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 2012;14(Suppl 5):v1–49.

3. Fuentes-Raspall R, Vilardell L, Perez-Bueno F, Joly C, Garcia-Gil M, Garcia-Velasco A, et al. Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994–2005. J Neurooncol. 2011;101:117–23.

4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC–NCIC trial. Lancet Oncol. 2009;10:459–66.

5. Malkoun N, Chargari C, Forest F, Fotso MJ, Cartier L, Auberdiac P, et al. Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. J Neurooncol. 2012;106:127–33.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Temozolomide based treatment in glioblastoma: 6 vs. 12 months;Oncology Letters;2024-07-02

2. Enhancing glioblastoma treatment through the integration of tumor-treating fields;Frontiers in Oncology;2023-10-17

3. Bottlenecks and opportunities in immunotherapy for glioma: a narrative review;Journal of Bio-X Research;2022-12

4. Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis;Journal of Neuro-Oncology;2022-11

5. Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma;BMJ Open;2022-09